What does the GSK analyst rating from Barclays mean for shareholders?

Barclays maintaining an Underweight means it expects GSK to lag peers. The raised price target narrows downside expectations. Shareholders should view this as cautious, and watch earnings and guidance for new analyst catalysts.

Did Barclays change the GSK price target in this update?

Yes. On Feb 20, 2026 Barclays raised its price target to **1,900 GBp** from **1,780 GBp** while maintaining Underweight. The move adjusts valuation but not the recommendation.

How does the GSK analyst rating affect the stock price?

Analyst ratings can influence short-term flows and sentiment. A maintained Underweight with a higher target may mute downside pressure but likely limits buying momentum until fundamentals change.

Where can I find the original Barclays note and market data?

Barclays' note on the target change was reported on TheFly [source](https://thefly.com/permalinks/entry.php/id4297604/6562286394/GSK-GSK-price-target-raised-by--GBp-at-Barclays). For live quotes, see MarketWatch [source](https://www.marketwatch.com/investing/stock/gsk?gaa_at=eafs&gaa_n=AWEtsqccP0gig

Analyst Ratings

Barclays Maintains Underweight on GSK plc (GSK) Feb 20 2026, PT 1,900 GBp

ByDanny Kontos February 23, 2026February 23, 2026

Barclays on Feb 20, 2026 maintained an Underweight rating on GSK plc, while raising its price target to 1,900 GBp. The move is the headline in this GSK analyst rating update. Barclays left its stance unchanged but lifted the target from 1,780 GBp. Investors should note the firm kept a cautious view despite the higher target. Meyka AI rates GSK with a grade of B+.